 The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS approximately equal numbers with relapsing-remitting and secondary progressive progressive relapsing MS and evidence of involvement of the anterior afferent visual system. 